Cantitate/Preț
Produs

Cell Culture Engineering: Advances in Biochemical Engineering/Biotechnology, cartea 101

Editat de Wei-Shu Hu
en Limba Engleză Hardback – 23 aug 2006
Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 160472 lei  6-8 săpt.
  Springer Berlin, Heidelberg – 18 noi 2010 160472 lei  6-8 săpt.
Hardback (1) 161003 lei  6-8 săpt.
  Springer Berlin, Heidelberg – 23 aug 2006 161003 lei  6-8 săpt.

Din seria Advances in Biochemical Engineering/Biotechnology

Preț: 161003 lei

Preț vechi: 196345 lei
-18%

Puncte Express: 2415

Preț estimativ în valută:
30822 33426$ 25966£

Carte tipărită la comandă

Livrare economică 03-17 septembrie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783540340065
ISBN-10: 3540340068
Pagini: 184
Ilustrații: XI, 168 p.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.44 kg
Ediția:2006
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Advances in Biochemical Engineering/Biotechnology

Locul publicării:Berlin, Heidelberg, Germany

Public țintă

Research

Descriere

Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade.

Cuprins

S.S. Farid: Established Bioprocesses for Producing Antibodies as a Basis for Future Planning.- K.F. Wlaschin, W.-S. Hu: Fedbatch Culture and Dynamic Nutrient Feeding.- K. Konstantinov, C. Goudar, M. Ng, R. Meneses, J. Thrift, S. Chuppa, C. Matanguihan, J. Michaels, D. Naveh: The 'Push-To-Low' Approach for Optimitzation of High-Density Perfusion Cultures of Animal Cells.- C. Goudar, R. Biener, C. Zhang, J. Michaels, J. Piret, K. Konstantinov: Towards Industrial Application of Quasi Real-Time Metabolic Flux Analysis for Mammalian Cell Culture.- G. Seth, P. Hossler, J.C. Yee, W.-S. Hu: Engineering Cells for Cell Culture Bioprocessing-Physiological Fundamentals.-

Caracteristici

Covers trends in modern biotechnology
All aspects of this interdisciplinary technology, where knowledge, methods and expertise are required from chemistry, biochemistry, microbiology, genetics, chemical engineering and computer science, are treated
More information as well as the electronic version available at springer.com